Last edition
News about "Jazz Pharmaceuticals "
Jazz and Saniona Enter Global License Deal for Preclinical Epilepsy Candidate SAN2355
Jazz Pharmaceuticals and Saniona have entered into a global licensing agreement, giving Jazz exclusive worldwide rights to develop and commercialise SAN2355, a highly selective Kv7.2/Kv7.3 activator currently in preclinical development for epilepsy and other neurological conditions. <br />
Jazz Pharmaceuticals | 21/08/2025 | By Dineshwori | 136
The US Food and Drug Administration (FDA) has granted accelerated approval for Jazz Pharmaceuticals' Modeyso (dordaviprone) for the treatment of adult and pediatric patients 1 year of age and older with H3 K27M-mutant diffuse midline glioma – a rare and highly aggressive brain tumour – with progressive disease following prior therapy.
Jazz Pharmaceuticals | 08/08/2025 | By Dineshwori | 221
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy